NCT03375164View on ClinicalTrials.gov

A Gene Transfer Therapy Study to Evaluate the Safety of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

January 4, 2018

Primary Completion Date

April 25, 2023

Study Completion Date

April 25, 2023

Conditions
Duchenne Muscular Dystrophy
Interventions
GENETIC

delandistrogene moxeparvovec

Single IV infusion of delandistrogene moxeparvovec.

Trial Locations (1)

43205

Nationwide Children's Hospital, Columbus

All Listed Sponsors
lead

Sarepta Therapeutics, Inc.

INDUSTRY

NCT03375164 - A Gene Transfer Therapy Study to Evaluate the Safety of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) | Biotech Hunter | Biotech Hunter